ArticleJournal of neurology2025
Efgartigimod-rituximab sequential therapy in Anti-NMDAR encephalitis: real-world evidence for a novel salvage-maintenance strategy.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Sequential FcRn blockade and B-cell depletion for treatment-refractory relapsing autoimmune encephalitis: a three-patient case series.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA subset of anti-NMDAR encephalitis (NMDARe) patients demonstrate suboptimal response to initial immunotherapies (steroids/intravenous immunoglobulin [IVIg]), which poses significant clinical dilemmas regarding therapeutic escalation. This real-world study retrospectively analyzes salvage immunotherapy outcomes in patients with treatment resistance across acute and maintenance phases.
methodsWe performed regression analysis to identify risk factors for treatment failure. Comparative assessments were then conducted for acute-phase salvage therapies (therapeutic plasma exchange [TPE], repeated IVIg [reIVIg], cyclophosphamide, rituximab [RTX], and efgartigimod [EFG] + RTX) and maintenance-phase immunotherapies (azathioprine, mycophenolate mofetil [MMF], and repeated RTX [reRTX]), with evaluation of both efficacy and safety profiles.
resultsIn this real-world cohort of 219 NMDARe patients, 86 (39.3%) exhibited inadequate response to initial immunotherapies, with status epilepticus identified as an independent predictor of treatment resistance. EFG + RTX showed synergistic acute salvage efficacy, with significantly improved response rates versus reIVIg and cyclophosphamide, though only numerically higher than TPE and RTX monotherapy. The combination therapy also demonstrated statistically significant benefits in terms of response latency, functional recovery and hospitalization duration while maintaining a favorable safety profile. During maintenance phase, reRTX administration showed superior long-term outcomes compared to conventional immunosuppressants (azathioprine or MMF), with reduced relapse rates and better tolerability.
conclusionThese findings provide the first real-world evidence for EFG-RTX sequential therapy benefits in initially unresponsive NMDARe, with observed synergistic effects supported by mechanistic evidence though not formally tested. This novel salvage-maintenance approach demonstrates promising efficacy and safety, warranting validation through larger controlled studies.
Indexed as
Identifiers
41160192What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.